Efficacy and Safety of COVID-19 Vaccines in Children

The initiation of a phase 2 study of the investigational 31-valent pneumococcal conjugate vaccine is expected by the end of January 2025.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

"The novel RSV prevention strategies may reduce ICU morbidity and mortality for children," the study authors concluded.

Contemporary Pediatrics sat down with Dr. Donna Hallas to discuss how to communicate with parents as well as how to address vaccines missed because of the pandemic.

Infants, young children, and older adults are at the highest risk for pneumococcal infection, and viral illnesses, such as influenza, may predispose sensitive groups to pneumococcal infection.

Overall, 2 doses of TAK-003 successfully induced the production of neutralizing antibodies against all 4 dengue serotypes in at least 90% of adults, children, and adolescents, regardless of whether they were seronegative or seropositive at baseline.